Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer

• Published in: Gynecologic oncology 2022-07, Vol.166 (1), p.61-68
• Main Authors: Mokhtech, Meriem, Gao, Sarah J., Kassick, Megan, Menderes, Gulden, Damast, Shari
• Format: Article
• Language: English
• Subjects: Clinically node negative; Pathologically node positive; Radiation oncology; Radiation therapy; Vulva; Vulvar cancer
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2022.05.001

The management of vulvar cancer with clinically negative groin lymph nodes but with positive sentinel lymph node biopsy (SLNB) is controversial, with options including inguinofemoral lymphadenectomy (IFL) and/or adjuvant chemotherapy and radiotherapy. We used the National Cancer Database (NCDB) to examine trends in the management of clinically node negative, pathologically node positive (cN-/pN+) patients. The NCDB was used to identify cN-/pN+ vulvar cancer patients. Demographic and clinical data were compared with chi-squared and Wilcoxon rank-sum tests. OS was analyzed with the Kaplan-Meier method and log-rank test. Cox proportional hazards regression was used to determine factors associated with OS. A total of 885 cN-/pN+ vulvar cancer patients were identified between 2012 and 2016, during which the rate of SLNB alone increased from 3.6% to 11.7%, while the rate of IFL +/− SLNB decreased from 89.7% to 78.1% (p < 0.05). Radiation was used in 68.5% and 64.6% of the SLNB-alone and IFL +/− SLNB cohorts, respectively, with chemoradiation in 37.1% and 33.6%, respectively. OS was not different between patients who received SLNB-alone vs. IFL +/− SLNB (p = 0.644). Receipt of chemotherapy and radiation was associated with improved OS (p < 0.001). Among cN-/pN+ vulvar cancer patients in the NCDB, the practice of performing IFL decreased over time as SLNB-alone became more common and the majority received radiation +/− chemotherapy. There was no difference in OS between SLNB-alone vs. IFL +/− SLNB. Patients treated with adjuvant chemoradiation had improved survival. Whether the favorable outcomes in the SLNB-alone cohort may be attributed to radiotherapy dose escalation or use of chemotherapy warrants further study. •From 2012 to 2016 the rate of SLNB alone increased, while the rate of IFL +/− SLNB decreased.•Overall, radiation was used in two thirds of patients, with chemoradiation in approximately one third.•OS was not different between patients who received SLNB-alone vs. IFL +/− SLNB.•Receipt of chemotherapy and radiation was associated with improved OS.